PCOS Is Now PMOS: India's Clinical and Patient Guide to the 2026 Rename

---

You Were Never "Just Hormonal"

If you have spent years being told you have "PCOS — polycystic ovarian syndrome," you may have noticed how little that name explained. Your doctor circled a blurry ultrasound image and mentioned cysts. But what about the relentless fatigue, the insulin spikes after a single roti, the thyroid readings that were never quite right, the weight that refused to budge even on a 1,200-calorie diet? The ovaries were the messenger. The whole system was the problem.

In May 2026, a global clinical consortium confirmed what millions of Indian women suspected: the name was always wrong. The condition has been officially renamed PMOS — Polyendocrine Metabolic Ovarian Syndrome — in a landmark paper published in The Lancet (PubMed ID: 42119588; doi: 10.1016/S0140-6736(26)00717-8). PCOS is not gone. The disease is the same. But finally, the label is honest about what it actually is.

---

What Changed, and Why It Took 11 Years

The Global Name Change Consortium did not act quickly. The process behind the PMOS rename spanned eleven years, involved 56 organisations, and gathered responses from more than 22,000 individuals — clinicians, researchers, patients, patient advocates, and policymakers from across the world. The defining stakeholder survey in 2025 alone captured 14,360 participants. When the expert panel voted, 87 of 90 panellists chose PMOS immediately. There was no significant dissent.

India was not a bystander. Dr. Madhuri Patil of Dr. Patil's Fertility and Endoscopy Clinic in Bengaluru was among the Indian clinicians represented in the consortium process, a meaningful marker that India's clinical experience — including our distinctly high prevalence rates and our lean-PMOS phenotype burden — was factored into the final nomenclature.

So, why PMOS? Each word in the new name earns its place:

• Polyendocrine — This is not a single-gland condition. The thyroid axis, adrenal axis, ovarian axis, and pancreatic function are all frequently dysregulated. Treating only the ovaries while ignoring insulin resistance or subclinical hypothyroidism is not complete care.
• Metabolic — Insulin signalling, lipid metabolism, adipokine function, and body composition are core features of this syndrome, not secondary consequences.
• Ovarian — The ovaries remain centrally involved: cycle irregularity, anovulation, and fertility challenges are real. The ovaries are not removed from the picture; they are no longer the entire picture.

"Syndrome" stays because PMOS continues to be understood as a cluster of related but heterogeneous presentations rather than a single, uniform disease.

---

What PMOS Actually Means for the Indian Body

This rename matters more in India than almost anywhere else on the planet. Approximately 44 million Indian women are living with this condition. The reproductive-age prevalence is 19.3% under Rotterdam criteria — nearly one in five. In Delhi NCR among 18–25 year olds, it is 17.4%. In Kashmir, estimates range from 30–35%. According to GBD 2021 data, India recorded the highest change in PMOS prevalence across South Asia between 1990 and 2021 — an increase of 86.9%.

The dominant phenotype among Indian women is Phenotype C (40.8%): hyperandrogenism combined with polycystic ovarian morphology, often without classic ovulatory dysfunction as the presenting complaint. This phenotype correlates strongly with insulin resistance even in lean women — a pattern that western clinical literature historically underweighted.

The metabolic co-morbidity profile in Indian PMOS is striking:

• Dyslipidaemia: present in up to 91.9% of cases
• Non-alcoholic fatty liver disease (NAFLD): 32.9%
• Metabolic syndrome: 24.9%

Genetically, Indian women with PMOS show a higher frequency of the IRS1 Gly972Arg variant, directly linked to insulin resistance in our population. Critically, adiponectin deficiency — which drives metabolic dysfunction — occurs in Indian women with PMOS independent of obesity. This means a lean woman with a normal BMI may still carry the same metabolic risk as someone with clinical obesity. The body weight is not the diagnosis; the metabolic and endocrine signalling is.

What "polyendocrine" captures that "polycystic" never could: when a patient presents with thyroid antibodies, borderline fasting insulin, irregular periods, and acanthosis nigricans despite a "normal" BMI, the clinical picture is no longer mysterious. It is PMOS.

---

What Actually Changes for You as an Indian Patient

This is the section that matters practically — and the honest answer is: less than you might expect in the short term, more than you might expect over the next decade.

Your records and insurance are unaffected. The ICD coding transition is expected to complete by approximately 2028 — a standard 3-year international rollout. Until then, your hospital discharge summary, your health insurance documents, and your diagnostic paperwork will likely still say "PCOS" or use PCOS-era ICD codes. That is not an error. It is a system transition in progress.

Your doctor may not have switched yet. Many clinicians in India will continue using "PCOS" in clinical notes for some time, particularly in tier-2 and tier-3 cities where guideline adoption takes longer. If your doctor has not heard of PMOS, that does not mean your diagnosis is wrong or that the naming change is disputed — it simply means the guideline refresh is still rolling out.

Your treatment plan does not automatically change. The rename did not introduce new drugs, new diagnostic criteria, or new treatment protocols overnight. If you are currently managing PMOS with metformin, clomiphene, lifestyle changes, or any other approach, you should not stop or restart anything based on the name change alone. The science behind your current treatment is not invalidated.

Search terms still work both ways. "PCOS" is not an illegal search term. It will continue returning relevant results for years. If you are researching symptoms, clinical trials, or nutrition protocols, searching for either PCOS or PMOS will surface the same underlying evidence base — the disease is the same.

What has changed is the clinical conversation you are entitled to have. The rename gives you language to ask: "Are we looking at my full endocrine picture? Has anyone tested my fasting insulin? My thyroid peroxidase antibodies? My lipid panel?" The name PMOS opens that door.

---

The Qura Perspective: Why This Validates Whole-System Care

At Qura, we find this rename meaningful — not because it is a marketing moment, but because it validates the clinical framework we have always worked within.

Ayurvedic and integrative frameworks have never treated this condition as ovary-only. The concept of Aartava Kshaya in classical Ayurveda already recognised the link between Medo dhatu (fat tissue), Medavaha srotas (metabolic channels), and menstrual irregularity. The understanding that metabolic function and reproductive function are inseparable is not new in Indian medicine — it is foundational.

The PMOS rename says the same thing in a language that modern clinical medicine can hear.

If you have recently been diagnosed, or if you have been managing this condition for years and feel like parts of your picture have never been fully addressed, we offer a free 45-minute consultation with one of our practitioners. We would be glad to look at the whole system with you.

---

Three Things to Do This Week

1. Ask for a full metabolic panel at your next appointment. Fasting insulin, HbA1c, full lipid panel, and thyroid function (TSH, T3, T4, and ideally TPO antibodies) give a more complete PMOS picture than a pelvic ultrasound alone.

2. Update your health records vocabulary. When describing your condition to new doctors, you can say "I have PMOS (formerly PCOS)" — most clinicians will recognise both terms, and the dual reference helps ensure continuity of care.

3. Share this with someone who needs it. With 44 million Indian women affected, someone in your family or friend circle is managing this condition. The rename may help them ask better questions at their next appointment.

---

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Please consult a qualified healthcare professional for personalised guidance regarding your health.

---

References

Teede HJ, Khomami MB, Morman R, et al; Global Name Change Consortium. [PMOS rename consensus statement]. Lancet. 2026 May 12. PubMed ID: 42119588. doi: 10.1016/S0140-6736(26)00717-8.